Palbociclib is known as an emerging option for patients with HR+/HER2− advanced or metastatic breast cancer, while tacrolimus and sirolimus are already extensively studied in ALL patients receiving stem cell transplantation. This evidence concerns the gene HR and acute lymphoblastic leukemia.